Scholarlink

Background <p>Selective lateral pelvic lymph node dissection (LPLND) after chemoradiotherapy for persistent nodes is a standard approach for rectal cancer patients with persistently enlarged lateral pelvic nodes (LPLN). The widely adopted Ogura criteria for LPLND selection were based on long-course chemoradiotherapy (LCRT) outcomes. With the rapid adoption of total neoadjuvant therapy (TNT), the relevance of these criteria in the TNT setting remains uncertain. This study aimed to evaluate the role of TNT in managing LPLNs and to identify risk factors for pathologically positive LPLNs (pLPLNs).</p> Methods <p>This study retrospectively analyzed patients with locally advanced rectal cancer who underwent LPLND between January 2014 and July 2024. Patients with LPLNs larger than 7 mm at presentation and persistent nodes larger than 4 mm after neoadjuvant therapy underwent LPLND. Risk factors for pLPLN were assesed using multivariable analysis. Local recurrence-free survival (LRFS), disease-free survival (DFS), and overall survival (OS) were estimated using the Kaplan-Meier method.</p> Results <p>Among 228 patients who underwent LPLND, 57 (25 %) had pLPLNs. The internal iliac region was the most common site (47 %). Total neoadjuvant therapy was administered to 118 patients (52 %), with 30 (25.4 %) showing pLPLN after TNT. The significant predictors of pLPLN were cT4b stage (odds ratio [OR], 2.60; 95 % confidence interval [CI], 1.31–5.33; <i>p</i> = 0.007) and multiple enlarged LPLN stations (OR, 3.82; 95 % CI, 1.36–10.98; <i>p</i> = 0.011). Total neoadjuvant therapy was not significantly associated with pLPLN (OR, 2.98; 95 % CI, 0.40–21.88; <i>p</i> = 0.284). The 3-year LRFS was similar between the TNT (90 %) and LCRT (85 %) groups (hazard ratio [HR], 1.31; 95 % CI, 0.56–3.08; <i>p</i> = 0.527).</p> Conclusion <p>The LCRT- and TNT-treated patients had similar rates of positive lateral nodes. Therefore, the selection criteria for choosing patients for LPLND does not need to change based on the neoadjvuant approach used.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Is Total Neoadjuvant Therapy the Solution to the Lateral Pelvic Lymph Nodes in Rectal Cancer? Retrospective Analysis From a High-Volume Tertiary Care Center

  • 期刊论文

  • 发表日期：

    2026年4月22日

查看全文
  • Mithun Nariampalli Karthyarth,
  • Subhathira Manohkaran,
  • Mufaddal Kazi,
  • Sudarshana Sreramaseshadri,
  • Akash Mor,
  • Ashwin Desouza,
  • Avanish Saklani

摘要

Background

Selective lateral pelvic lymph node dissection (LPLND) after chemoradiotherapy for persistent nodes is a standard approach for rectal cancer patients with persistently enlarged lateral pelvic nodes (LPLN). The widely adopted Ogura criteria for LPLND selection were based on long-course chemoradiotherapy (LCRT) outcomes. With the rapid adoption of total neoadjuvant therapy (TNT), the relevance of these criteria in the TNT setting remains uncertain. This study aimed to evaluate the role of TNT in managing LPLNs and to identify risk factors for pathologically positive LPLNs (pLPLNs).

Methods

This study retrospectively analyzed patients with locally advanced rectal cancer who underwent LPLND between January 2014 and July 2024. Patients with LPLNs larger than 7 mm at presentation and persistent nodes larger than 4 mm after neoadjuvant therapy underwent LPLND. Risk factors for pLPLN were assesed using multivariable analysis. Local recurrence-free survival (LRFS), disease-free survival (DFS), and overall survival (OS) were estimated using the Kaplan-Meier method.

Results

Among 228 patients who underwent LPLND, 57 (25 %) had pLPLNs. The internal iliac region was the most common site (47 %). Total neoadjuvant therapy was administered to 118 patients (52 %), with 30 (25.4 %) showing pLPLN after TNT. The significant predictors of pLPLN were cT4b stage (odds ratio [OR], 2.60; 95 % confidence interval [CI], 1.31–5.33; p = 0.007) and multiple enlarged LPLN stations (OR, 3.82; 95 % CI, 1.36–10.98; p = 0.011). Total neoadjuvant therapy was not significantly associated with pLPLN (OR, 2.98; 95 % CI, 0.40–21.88; p = 0.284). The 3-year LRFS was similar between the TNT (90 %) and LCRT (85 %) groups (hazard ratio [HR], 1.31; 95 % CI, 0.56–3.08; p = 0.527).

Conclusion

The LCRT- and TNT-treated patients had similar rates of positive lateral nodes. Therefore, the selection criteria for choosing patients for LPLND does not need to change based on the neoadjvuant approach used.